Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Core Insights - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases [3] - The CEO, Warner Biddle, will present at the Jefferies Global Healthcare Conference on November 17, 2025 [1] - The company’s lead CAR T-cell therapy candidate, KYV-101, is in late-stage clinical development for stiff person syndrome and myasthenia gravis, with ongoing trials for lupus nephritis [3] Company Overview - Kyverna Therapeutics is dedicated to liberating patients through the curative potential of cell therapy [3] - The company is advancing next-generation CAR T-cell therapies in both autologous and allogeneic formats, aiming to expand into broader autoimmune indications [3] - The proprietary whole blood rapid manufacturing process is expected to increase patient reach with KYV-102 [3] Upcoming Events - A live webcast of the CEO's presentation will be available on the company's website, with a replay accessible for approximately 90 days post-conference [2]